Organ Transplantion

Three artificial hearts to be implanted

French authorities have given the green light for continuing the clinical trial for the first fully implantable mechanical heart after a four-month review of the device and the causes of death of the first patient to receive the prosthesis

The ‘self-regulating’ artificial heart refers to the ability to speed up or...
The ‘self-regulating’ artificial heart refers to the ability to speed up or slow down its flow rate – if the patient is performing a vigorous physical activity, for instance, the heart will respond by beating faster. This is made possible via ‘multiple miniature embedded sensors’ and proprietary algorithms running on the integrated microprocessor.

The manufacturer, Carmat, can now continue its recruitment of three other patients authorised for this first trial to test device safety and feasibility. All implantations will be performed in France. Congratulating participants on the quality of their work in collecting and analising the data from this first implantation, Carmat CEO Marcello Conviti said in a company announcement that ‘complementary measures’ have been put in place to continue the trial in order to assure the best conditions for safety.

In an e-mail response to European Hospital, the company said the measures ‘concern notably manufacturing processes or protocols which the company does not wish to discuss.’ The company also said that it will not communicate any further information until the full trial for safety has been completed.

The first artificial heart that was implanted

The first patient to receive a totally implantable artificial heart died 75 days after the procedure. The cause of death on 2 March 2014 was not disclosed in a short announcement made by the Hôpital Georges-Pompidou in Paris. Christian Latremouille MD, at the Hôpital Georges-Pompidou, noted that a survival of 74 days for the first patient with end-stage heart failure widely exceeded the 30-day endpoint for the safety study. The 76-year-old patient was ‘fully aware of the risks and by his confidence, his courage and his willingness has made a remarkable contribution to the efforts undertaken to combat a rapidly progressing disease,’ the medical team stated. The heart was implanted on 18 December 2013, by the surgical team led by Dr Latremouille with the participation and guidance of the inventor of the device, Alain Carpentier MD.

The artificial heart adapts blood supply

This was the first time an artificial heart requiring no external pumps had been implanted. Only two wires exited the body at the abdomen, one to supply power and a second to monitor device performance. This is also the first artificial heart capable of adapting the blood supply according to a patient’s activity, varying from three to nine litres per minute, rather than keeping to a constant supply. In an interview with the French weekly, Journal du Dimanche, Carpentier said the first patient’s death ‘is not linked to a complication of the patient, nor to the fundamental principles of this prosthesis.’ He said the risk of thrombosis was limited, that the patient did not demonstrate any cerebral deficiency, and that an autopsy confirmed there was not the least bit of clotting in the device nor in the circulatory system. ‘In this sense, the trial was a success,’ he concluded.


Read all latest stories

Related articles


News • Promising alternative to heart transplants

'Artificial aorta' to reduce blood pressure

Engineers at EPFL’s Center for Artificial Muscles have developed a silicone aorta that can reduce how hard patients’ hearts have to pump. Their breakthrough could offer a promising alternative to…


Article • Home monitoring

Success for pacemaker recipients

Biotronik’s Home Monitoring is an award-winning remote cardiac monitoring system that automatically collects data from a patient’s cardiac device, enabling the physician to review cardiac…


News • Deadly heart inflammation

Hope for first blood test to detect myocarditis

The first blood test to diagnose inflammation of the heart muscle (myocarditis) could be in use in as little as a year, following the discovery of a molecular signal in the blood.

Related products

Guerbet · Illumena Néo


Guerbet · Illumena Néo

KABE Labortechnik – Consumables Test Tubes

Blood Collection

KABE Labortechnik – Consumables Test Tubes

Sarstedt – SC 2700 Centrifuge


Sarstedt – SC 2700 Centrifuge

allMRI GmbH · Foldable MRI wheelchair

Accessories / Complementary systems

allMRI GmbH · Foldable MRI wheelchair

allMRI GmbH
Subscribe to Newsletter